Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that abstracts for four posters — two addressing clinical results and two addressing preclinical results with the company’s pan-caspase inhibitor, emricasan — have been accepted for presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston November 11-15, 2016.
Accepted abstracts were published today on the AASLD website at www.aasld.org/ for posters entitled:
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with Cirrhosis and Elevated MELD Score Improves Liver Function,” (poster #2095);
- “Emricasan (IDN-6556) Orally for 6 Months in Patients with Non-alcoholic Steatohepatitis (NASH) Cirrhosis Decreases the Progression of MELD score and Improves Liver Function,” (poster #2099);
- “Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases,” (poster #2098); and
- “The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression,” (poster #2097).
- Both poster #2095 and poster #2097 were accepted as “Presidential Posters of Distinction,” indicating review scores that place them within the top 10 percent of all posters submitted.
“We continue accumulating clinical evidence of emricasan’s disease-modifying potential as we advance toward an initial registration in patients with liver cirrhosis caused by nonalcoholic steatohepatitis (NASH),” said Conatus co-founder, President and Chief Executive Officer Steven J. Mento, Ph.D., “while simultaneously confirming emricasan’s multiple mechanistic effects on liver structure and function through preclinical studies. We are pleased with the opportunity to highlight the latest developments in both areas at the upcoming AASLD meeting, providing a deeper scientific understanding of the medical benefits observed in our clinical trials.” (Original Source)
Shares of Conatus Pharmaceuticals are up nearly 10% to $2.16 in pre-market trading. CNAT has a 1-year high of $4.62 and a 1-year low of $1.40. The stock’s 50-day moving average is $1.91 and its 200-day moving average is $2.23.
On the ratings front, Conatus has been the subject of a number of recent research reports. In a report issued on September 20, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on CNAT, with a price target of $6.00, which represents a potential upside of 200% from where the stock is currently trading. Separately, on August 30, FBR’s Vernon Bernardino reiterated a Buy rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Stephen Willey and Vernon Bernardino have a total average return of 20.0% and -15.8% respectively. Willey has a success rate of 54% and is ranked #139 out of 4197 analysts, while Bernardino has a success rate of 26% and is ranked #4083.
Overall, 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $10.50 which is 425.0% above where the stock opened today.
Conatus Pharmaceuticals, Inc. is a biotechnology company engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease.